



EBOLA STRATEGY

Ebola and Marburg virus disease epidemics: preparedness, alert, control and evaluation

August 2014

© World Health Organization 2014. All rights reserved.

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

Contents

Acknowledgements.....	5
List of abbreviations and acronyms	6
Chapter 1 – Introduction	7
1.1 Purpose of the document and target audience	8
1.2 Background	8
Chapter 2 – General strategy	14
2.1 Before: pre-epidemic phase.....	15
2.2 Alert: suspected Ebola or Marburg	16
2.3 During: epidemic phase.....	16
2.4 After: Post-epidemic phase.....	16
2.5 Use of the document	17
Chapter 3 – Before: What should be done in the pre-epidemic phase?.....	20
3.1 Establishment of a viral haemorrhagic fever surveillance system	21
3.2 Infection control precautions in health-care settings	22
3.3 Health promotion programme	23
3.4 Collaborate with mine health services (Marburg) and wildlife health services (Ebola)	23
3.5 Pre-alert: What should be done if the specimen taken from animals tests positive for Ebola or Marburg?.....	24
Chapter 4 – Alert: What should be done when Ebola or Marburg is suspected?	25
4.1 Investigating suspected Ebola or Marburg	26
4.2 Obtaining laboratory results	29
4.3 Taking a decision on the basis of laboratory results and the outcome of the investigation ..	29
Chapter 5 – During: What should be done once the epidemic is confirmed?	30
5.1 Marburg and/or Ebola epidemic control strategy.....	31
5.2 Coordination and resource mobilization	32
5.3 Coordination and resource mobilization.....	35
5.4 Behavioural and social interventions.....	38
5.5 Behavioural and social interventions.....	43
5.6 Clinical case management.....	44
5.7 Psychological management.....	49
5.8 Research projects and ethical issues.....	51
5.9 Logistics and safety	55
5.10 Environmental management.....	56

Chapter 6 – After: What should be done once the epidemic is over?	59
6.1 Declare the end of the epidemic	60
6.2 Resume the activities of the pre-epidemic phase.....	60
6.3 Medical follow-up of survivors.....	60
6.4 Monitoring of recovering patients and social problems.....	60
6.5 Produce the end-of-epidemic report.....	61
6.6 Keep records on the epidemic	61
6.7 Evaluate the management of the epidemic.....	61
Chapter 7 – Annexes	64
<i>General information about Ebola and Marburg virus diseases</i>	
Annex 1. WHO Ebola haemorrhagic fever fact-sheet (no. 103)	65
Annex 2. WHO Marburg haemorrhagic fever fact-sheet (November 2012)	65
<i>Surveillance and epidemiology</i>	
Annex 3a. Standard case definition of viral hemorrhagic fever for routine surveillance	66
Annex 3b. Standard case definition of viral haemorrhagic fever for community-based surveillance	66
Annex 3c. Examples of Marburg or Ebola virus disease case definitions that may be used during the outbreak	67
Annex 4. Contact tracing: Standard definition of Ebola or Marburg contacts.....	69
<i>Laboratory</i>	
Annex 6. Guidelines for the collection of clinical specimens during field investigation of outbreaks	73
Annex 7. Guidance on regulations for the Transport of Infectious Substances 2011-2012	73
Annex 8. List of laboratories and WHO Collaborating Centres for the diagnosis of Ebola or Marburg VHF.....	73
<i>Social and behavioural interventions and communications</i>	
Annex 9. Outbreak Communication. Best practices for communicating with the public during an outbreak	75
Annex 10. Communication for Behavioural Impact (COMBI): A toolkit for behavioural and social communication in outbreak response.	75
Annex 11. COMBI Toolkit: Field Workbook for COMBI planning steps in outbreak response. ..	75
Annex 12. Behavioural and Social interventions: a checklist for conducting a rapid situation analysis during suspect Ebola and Marburg events.....	76
Annex 13. Contribution of medical anthropology to Ebola and Marburg viral haemorrhagic fever outbreak control.....	78
<i>Clinical management of patients</i>	
Annex 14. Hospitalized patients' charter (May 2013)	84
Annex 18. Transmission risk reduction of filoviruses in home-care settings.....	85
Annex 19. Protocol for the reintegration of returning patients into their families and their community.....	87
<i>Psychosocial management</i>	
Annex 20. Mental health in emergencies	88

Annex 21. IASC Guidelines on Mental Health and Psychosocial support in Emergency settings	88
Annex 22. Mental health and psychological support in emergency settings: what should humanitarian health actors know?	88
Annex 23. Psychological first aid: Guide for field workers	88
<i>Research ethics</i>	
Annex 24. Medical Ethics Manual – World Medical Association	89
Annex 25. Research Ethics in International Epidemic Response. WHO Technical Consultation	89
Annex 26. Ethical considerations in developing a public health response to pandemic influenza	89
Annex 27. Guidance on ethics of tuberculosis prevention, care and control	89
Annex 28. Model guidelines for writing informed consent documents	89
Annex 29. Website of the interactive Health Research Web (HRWeb) platform	89
Annex 30. Training and Resources in Research Ethics Evaluation site	89
Annex 31. The Siracusa Principles on the Limitation and Derogation Provisions in the International Covenant on Civil and Political Rights	89
<i>Logistics</i>	
Annex 32. Description of disposable, nonperishable personnel protective equipment for indoor utilization in health-care facilities (Module PPE A: Basic Module of Personnel Protective Equipment)	90
Annex 33. Description of heavy-duty personnel protective equipment associated with Basic Module PPE A, for outdoor utilization during disinfection of contaminated areas, objects, and cloth, and when dealing with dead bodies and burials (Module PPE B: Heavy Duty Personnel Protective Equipment)	91
Annex 34. Logistics assessment form	92
<i>Ebola and Marburg subject-specific bibliographies</i>	
Annex 35. Ebola and Marburg bibliography, relevant videos, and web sites	100
<i>International Health Regulations (IHR)</i>	
Annex 36. WHO International Health Regulations (IHR)	107

Acknowledgements

This document is a result of collaboration within WHO, between the Communicable Disease Surveillance and Response Programme (CSR) at WHO Regional Office for Africa (AFRO) and the Global Alert and Response (GAR) department at WHO Headquarters, with significant contributions from the WHO Regional Office for the Eastern Mediterranean (EMRO), the WHO Regional Office for Europe (EURO), and a range of partners around the world.

It was prepared on the basis of the experience gained during Ebola and Marburg outbreak control operations since 1995, following informal meetings of the editorial working group held in Burkina Faso (Ouagadougou), Gabon (Libreville), and Republic of the Congo (Brazzaville) between 2004 and 2009, with the assistance of international experts.

WHO wishes to thank all those who participated in the preparation of this document for their essential contributions, namely:

- Alain Epelboin, National Science Research Centre and Natural History Museum, Paris (France).
- Philippe Calain, Médecins Sans Frontières, Geneva (Switzerland).
- Rosa Crestani, Michel Van Herp, Médecins Sans Frontières, Brussels (Belgium).
- Pierre Rollin, US Centers for Disease Control and Prevention, Atlanta (United States of America).
- Gary Kobinger, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg (Canada).
- Eric Leroy, Development Research Institute and International Medical Research Centre of Franceville, Franceville (Gabon).
- WHO/AFRO, DPC/CSR: Yokouidé Allaranger, Adama Berthé, Mamoudou Djingarey, Bréhima Koumaré, Denis Kandolo, Kader Kondé, Mamadou-Lamine Koné, Nestor Ndayimirije, Florimond Tshioko, Celia Woodfil, Adamou Alzouma Yada, and Ali Ahmed Yahaya.
- WHO/EMRO: Martin Opoka and Hassan El Bushra Ahmed.
- WHO/EURO: Guenael Rodier and Christiana Salvi.
- WHO/Headquarters, IER/ETH: Marie-Charlotte Bouësseau and Andreas Reis.
- WHO/Headquarters, NMH/MSD/MER: Mark Humphrey Van Ommeren.
- WHO/Headquarters, HSE/GAR: Kamal Ait-Ikhlef, Jean-Christophe Azé, Eric Bertherat, Patrick Drury, Sergey Eremin, Pierre Formenty, Thomas Grein, Stéphane Hugonnet, Dominique Legros, Asiya Odugleh-Kolev, Carmen Pessoa-Silva, Cathy Roth, Michael J. Ryan, and Jordi Sacristan.

We wish to thank in particular Pierre Formenty (WHO/Headquarters) and Yokouidé Allaranger (WHO/AFRO) for their vital contribution and for coordinating the final edition of the document.

WHO extends its gratitude to the EuropeAid Cooperation Office of the European Commission (AIDCO) for its financial support.



This document has been produced with the financial assistance of the European Union. The views expressed herein may in no way be taken to reflect the official opinion of the European Union.

List of abbreviations and acronyms

AFRO	WHO Regional Office for Africa
COMBI	Communication for Behavioural Impact
DRC	Democratic Republic of Congo
EMRO	WHO Regional Office for the Eastern Mediterranean
EURO	WHO Regional Office for Europe
EVD	Ebola virus disease
IHR	International Health Regulations
MVD	Marburg virus disease
NFP	National Focal Point
NSAID	non-steroidal anti-inflammatory drug
OIE	World Organisation for Animal Health / Organisation mondiale de la santé animale
PPE	personal protective equipment
PRRS	porcine reproductive and respiratory syndrome
VHF	viral haemorrhagic fever
WHO	World Health Organization

Chapter 1 – Introduction

1. Introduction

1.1 Purpose of the document and target audience

Ebola or Marburg haemorrhagic fever outbreaks constitute a major public health issue in Sub-Saharan Africa. Of the 2 870 Marburg and Ebola cases documented between June 1967 and June 2011, 270 (9%) were health-care workers. In order to provide health-care workers in risk areas with a working tool to combat Ebola Virus Disease (EVD) or Marburg Virus Disease (MVD) effectively, the WHO Regional Office for Africa (AFRO), the WHO Regional Office for the Eastern Mediterranean (EMRO), WHO Headquarters and their partners have produced this document: Ebola and Marburg virus disease epidemics: Preparedness, alert, control and evaluation.

The main target audience of this document are district-level health-care workers (doctors, nurses, and paramedics), as well as intermediate- and central-level health-care workers responsible for epidemic control, and International Health Regulations (IHR) National Focal Points (NFPs).

The objective of this document is to describe preparedness, prevention, and control measures that have been implemented successfully during previous epidemics. These measures must be implemented during the following four phases:

- (1) Pre-epidemic preparedness
- (2) Alert (identify, investigate, evaluate risks)
- (3) Outbreak response and containment operations
- (4) Post-epidemic evaluation.

1.2 Background

The Marburg virus and Ebola virus genera belong to the Filoviridae family (filovirus). The Ebola virus is comprised of five distinct species: Bundibugyo, Côte d'Ivoire, Reston, Sudan, and Zaïre. There is only one Marburg virus species. The Marburg virus and Ebola Zaïre, Sudan, and Bundibugyo subtypes have been associated with large viral haemorrhagic fever (VHF) outbreaks characterized by high person-to-person transmission and a case fatality rate ranging from 25%–90%, whereas Côte d'Ivoire and Reston subspecies have not been associated with VHF outbreaks in humans to date.

Since its discovery in 1976, EVD has mostly occurred in Sub-Saharan Africa (Annex 1). The first cases of EVD were detected in the Democratic Republic of Congo (DRC) and Sudan (1976) and EVD epidemics have since occurred in DRC (1977, 1995, 2007, 2008, 2012), Sudan (1979, 2004), Gabon (1994, 1996, 2001, 2002), Uganda (2000, 2007, 2011, 2012), Republic of the Congo (2001, 2002, 2003, 2005), Guinea (2014), Liberia (2014), Sierra Leone (2014) and Nigeria (2014, following the entry of infected traveller from Liberia) (Figure 1). In 1994, Côte d'Ivoire reported one case of Ebola Côte d'Ivoire in a laboratory

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_27784

